Orexigen rises on FDA deal for Contrave cardio study
07 February 2012
Donna Young
Please Login to read the full article.
07 February 2012
Donna Young
donna.young@informa.com
Please Login to read the full article.
RELATED CONTENT
NEWS
- Orexigen puts brakes on obesity program, blames 'unprecedented' CV demands from US FDA
- Arena rockets 90% on US FDA panel endorsement for weight-loss drug
- REMS trips Qnexa with 3-month delay; but no hint of CVOT requirement
- US FDA panel calls for additional CV studies for weight-loss drugs
COMMENT
Other Informa Comment
EVENTS
07 June 2012
The Rembrandt Hotel, London
12 June 2012
Annecy, France
18 June 2012
Boston Convention & Exhibition Center, Boston, MA
JOB OF THE WEEK
Section Head (m/f)
DRA International/CIS Section
Section Head (m/f)
DRA International/CIS Section
